Document Type: Research Articles
Department of Biochemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
Department of Internal Medicine (Gastroenterology and Hepatology unit), Faculty of Medicine, Mansoura University, Mansoura, Egypt.
Oncology Center, Mansoura University, Mansoura, Egypt.
Background: Hepatocellular carcinoma (HCC) is a main cause of cancer death all over the world. Treatment and
outcome of HCC based on its early diagnosis. This study was conducted to estimate the role of talin-1 and midkine in
combination with total antioxidant capacity (TAC) as tumor markers in HCC patients. Methods: Serum levels of talin-1
and midkine were measured in 90 Egyptian subjects including 44 patients with HCC, 31patients with cirrhosis and 15
healthy controls using enzyme-linked immunosorbent assay (ELISA) technique. While a colorimetric method was used
for measurement of TAC. Results: Serum talin-1 in HCC patients was significantly lower than that in patients with
cirrhosis (P<0.001) and normal control (P<0.001). In addition, increased invasion and metastasis correlated with reduced
talin-1 level. Serum midkine in HCC patients was significantly higher compared to cirrhotic patients (P<0.001) and
normal control (P<0.001). Midkine at a cut off value of 1683 pg/ml showed a sensitivity of (81.82%) and specificity of
(83.87%). While alpha-fetoprotein (AFP) at a cut off value of 200 ng/ml had a sensitivity of (52.27%), while specificity
was (96.77%). Midkine was positive in 80.9% of HCC patients with negative AFP. Serum TAC was significantly
decreased in HCC patients when compared with control group (P<0.001). Conclusion: Talin-1 may be implicated
in the carcinogenesis and metastasis of HCC and can be used as a useful tumor marker for HCC. Midkine may be a
potential diagnostic marker for HCC and may be used in addition to AFP to increase the sensitivity of HCC detection.